Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzastaurin plus Bevacizumab in Recurrent Malignant Gliomas
NCT00586508Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2007
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzastaurin in malignant glioma, glioblastoma (GBM), sponsored by Eli Lilly and Company. Started Nov 2007; status: completed.
02
Drugs
enzastaurin
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT00586508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00586508.